NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 207 filers reported holding NEKTAR THERAPEUTICS in Q1 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $84,072 | -13.3% | 37,200 | +22.8% | 0.01% | -40.0% |
| Q3 2022 | $97,000 | -68.9% | 30,300 | -63.1% | 0.02% | -65.5% |
| Q2 2022 | $312,000 | +13.5% | 82,200 | +497.0% | 0.06% | -7.9% |
| Q1 2021 | $275,000 | -8.3% | 13,769 | -21.9% | 0.06% | -19.2% |
| Q4 2020 | $300,000 | -52.8% | 17,630 | +35.5% | 0.08% | -45.5% |
| Q2 2018 | $635,000 | -19.9% | 13,009 | +74.3% | 0.14% | -29.2% |
| Q1 2018 | $793,000 | -13.8% | 7,465 | -51.5% | 0.20% | +7.4% |
| Q4 2017 | $920,000 | +251.1% | 15,400 | +37.9% | 0.19% | +51.6% |
| Q1 2017 | $262,000 | -11.8% | 11,170 | -53.8% | 0.12% | +67.6% |
| Q4 2016 | $297,000 | – | 24,200 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |